Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Bevacizumab in HCC with Portal Vein Invasion
NCT07075562Completed
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Hospital of Hebei Medical University. Primary endpoints: Change in Tumor Load at 3 months, Change in Serum Angiogenic Factors at 3 months and 1 more. Started Jun 2021; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07075562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075562.